香港股市 將在 7 小時 7 分鐘 開市

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
10.48-0.32 (-2.96%)
收市:04:00PM EDT
10.61 +0.13 (+1.24%)
收市後: 05:53PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價10.80
開市10.73
買盤10.00 x 800
賣出價10.67 x 1800
今日波幅9.85 - 10.74
52 週波幅8.82 - 21.86
成交量1,313,007
平均成交量883,832
市值437.883M
Beta 值 (5 年,每月)1.22
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-4.25
業績公佈日2023年10月30日 - 2023年11月03日
遠期股息及收益率無 (無)
除息日
1 年預測目標價14.58
  • Benzinga

    New Data Shows Intercept's Fixed Dose Obeticholic Acid Combo Normalize Multiple Biomarkers In Liver Disease

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic potential of the combination of obeticholic acid (OCA) and bezafibrate vs. bezafibrate monotherapy on serum biomarkers in primary biliary cholangitis (PBC). As reflected in the abstract, data from the first 45 patients enrolled in Study 213 showed that over half of those receiving OCA5-10/B400 rapidly

  • Benzinga

    Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its Dreams To Enter NASH Space

    FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 fibrosis. Fifteen of 16 voting-eligible GIDAC members (with no abstentions) voted to defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional a

  • Benzinga

    Why Intercept Pharmaceuticals Shares Are Plunging Today

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around 20% after the FDA issued briefing documents ahead of the adcomm meeting scheduled for May 19 to review its liver disease candidate Obeticholic Acid (OCA). PDUFA Target Action Date set for June 22, 2023. The FDA briefing document highlighted an increased risk of diabetes and liver injury from using the obeticholic acid (OCA) oral tablets to treat nonalcoholic steatohepatitis (NASH). In the briefing documents, the FDA reviewers raised concer